FMR LLC reports 11.6% stake in Foghorn Therapeutics

FMR LLC filed an amendment to Schedule 13G/A reporting beneficial ownership of 6,792,356 shares of common stock of FOGHORN THERAPEUTICS INC.

Accepted by SEC EDGAR 05/06/2026 - 11:18 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

FMR LLC filed an amendment to Schedule 13G/A reporting beneficial ownership of 6,792,356 shares of common stock of FOGHORN THERAPEUTICS INC. The filing shows this equals 11.6% of the class and identifies the CUSIP 344174107. The cover indicates the reporting period 03/31/2026. The filing states certain voting and dispositive powers held by FMR LLC and by Abigail P. Johnson as reported, and references an attached 13d-1(k)(1) agreement in Exhibit 99.

Insights

Institutional Ownership Analyst

FMR LLC holds an 11.6% stake as of 03/31/2026; filing updates beneficial ownership details.

FMR LLC reports beneficial ownership of 6,792,356 shares of common stock, representing 11.6% of the class per the amendment. The filing lists sole dispositive power and itemizes voting/dispositive counts for the filer and for Abigail P. Johnson.

Disclosure references an Exhibit 99 agreement and a power of attorney for signature authority. This is a statutory beneficial‑ownership disclosure and does not by itself change corporate governance or capital structure.

Key Figures

Beneficial ownership: 6,792,356 shares Percent of class: 11.6% CUSIP: 344174107

3 metrics

Beneficial ownership 6,792,356 shares reported on Schedule 13G/A for 03/31/2026

Percent of class 11.6% percent of common stock reported in Item 4

CUSIP 344174107 identifier for Foghorn Therapeutics common stock on the cover

Key Terms

Schedule 13G/A, Beneficial ownership, 13d-1(k)(1) agreement

3 terms

Schedule 13G/A regulatory

"Amendment to Schedule 13G/A reporting beneficial ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficial ownership financial

"Amount beneficially owned: 6792356.00 (b) Percent of class: 11.6 %"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

13d-1(k)(1) agreement regulatory

"Please see Exhibit 99 for 13d-1(k) (1) agreement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does FMR LLC report in FHTX?

FMR LLC reports beneficial ownership of 6,792,356 shares, representing 11.6% of the common stock as shown in the amendment. The filing lists specific voting and dispositive powers attributed to the filer.

What period does the Schedule 13G/A amendment cover for FHTX?

The cover indicates the reporting period as 03/31/2026. The amendment updates ownership information as of that date and is signed in May 2026 by authorized representatives.

Does the filing name the CUSIP and class for FHTX shares?

Yes; the filing identifies the security as Common Stock with CUSIP 344174107. The cover and Item 2(e) list the class and exact CUSIP shown on the form.

Who signed the 13G/A amendment for FMR LLC and related parties?

The amendment is signed by Richard Bourgelas as duly authorized under a power of attorney on behalf of FMR LLC and on behalf of Abigail P. Johnson, with the power of attorney incorporated by reference to an exhibit.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 6)

FOGHORN THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

344174107

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 344174107

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 6,789,916.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 6,792,356.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,792,356.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

11.6 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP Number(s): 344174107

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 6,792,356.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,792,356.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

11.6 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: FOGHORN THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 500 TECHNOLOGY SQUARE,SUITE 700,CAMBRIDGE,MA,USA,02139
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 344174107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 6792356.00
(b)	Percent of class: 11.6 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 6792356.00
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of FOGHORN THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of FOGHORN THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	05/05/2026

Abigail P. Johnson

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of Abigail P. Johnson*
Date:	05/05/2026

Comments accompanying signature: *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on April 29,2026, accession number: 0000315066-26-000738.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.